CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
The recent communication regarding the recent Anti-SARS-CoV-2 Total assay in Tampa has brought about...
A new Learning Center website will launch on Monday, March 30, 2020. While the link to the new Learn...
The CTS forms listed below have been revised with an implementation date of September 2, 2019. ...
Just a reminder that the revised client forms implement today! Don't forget to toss your o...
Seasonal monitoring of epidemic triggers for West Nile Virus (WNV) NAT tested donations will begin J...
CTS originally communicated that Tampa will convert from the current Grifols Ultrio Plus NAT triplex...